Gout and hyperuricemia are common metabolic disorders. In recent years, the number of patients is increasing, and gout has become the second major metabolic disease in China after diabetes. According to The interpretation of 2018 updated European League Against Rheumatism evidence based recommendations for the diagnosis of gout give hyperuricemia and gout in installment, from asymptomatic to symptomatic will be divided into four stages: the stage high uric acid hematic disease, uric acid sodium (MSU) crystal deposition stage, gouty arthritis attack and attack stage, the stage progress/chronic gouty arthritis. With the aim of integrating the available data resources and facilitating comparative research, literature review and information extraction were performed. The database includes drug and compound names, physicochemical properties of drugs/compounds, targets, mechanisms of action and sources and links. Drugs that are already on the market and identified for the treatment of gout and hyperuricemia are defined as 'ClassⅠ', drugs that are already on the market and have potential therapeutic effects for gout and hyperuricemia are identified as 'ClassⅡ', and compounds, peptides and probiotics that have only been shown to reduce uric acid concentrations in vivo are defined as 'ClassⅢ'. This interface supports query functions, such as “CAS registration number” and “Smile” of drug. Therefore, this knowledge base will contribute to the development of uricate-lowering drugs, and promote the establishment of early screening methods for hyperuricemia and gout.
